Kazia Therapeutics (NASDAQ:KZIA) Stock Price Up 26.7% – What’s Next?

Kazia Therapeutics Limited (NASDAQ:KZIA) traded up 26.7% during mid-day trading on Tuesday . The stock traded as high as $5.35 and last traded at $4.79. 134,134 shares traded hands during trading, a decline of 23% from the average session volume of 175,096 shares. The stock had previously closed at $3.78.

Analysts Set New Price Targets

Separately, Maxim Group began coverage on Kazia Therapeutics in a research note on Thursday, February 6th. They issued a “buy” rating and a $15.00 target price on the stock.

Kazia Therapeutics Trading Up 26.7%

The company’s fifty day moving average price is $3.63 and its 200-day moving average price is $8.44.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Barclays PLC acquired a new position in Kazia Therapeutics Limited (NASDAQ:KZIA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned 2.38% of Kazia Therapeutics at the end of the most recent reporting period. 30.89% of the stock is currently owned by institutional investors and hedge funds.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.